Last reviewed · How we verify
Glutinal (GLUTATHIONE)
Glutinal, also known as Glutathione, is a small molecule drug that targets Glutathione S-transferase kappa 1. It belongs to the glutathione class and its exact commercial status is unknown. Glutathione is used to treat various conditions, but its specific indications are not provided. As a glutathione, it plays a crucial role in cellular antioxidant defenses, but its exact mechanism of action and safety considerations are not well-documented.
At a glance
| Generic name | GLUTATHIONE |
|---|---|
| Drug class | Vitamin C [EPC] |
| Target | Glutathione S-transferase kappa 1 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients. (PHASE1)
- Glutathione in Mild Cognitive Impairment (EARLY_PHASE1)
- Combination of Oral and Topical Whitening Agents for Reducing Skin Pigmentation (NA)
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
- Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection (PHASE2)
- Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis (PHASE2)
- Evaluation of the Efficacy of Oral Tranexamic Acid and Glutathione-assisted Microneedling in Treatment of Melasma (PHASE2,PHASE3)
- Tolerability of Enteral NAC in Infants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glutinal CI brief — competitive landscape report
- Glutinal updates RSS · CI watch RSS